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Abstract Iron-mediated oxidative stress has been implicated in
the pathology of the neurodegenerative disease Friedreich ataxia
(FRDA). Here, we show that normal upregulation of the stress
defense protein manganese superoxide dismutase (MnSOD) fails
to occur in FRDA fibroblasts exposed to iron. This impaired
induction was observed at iron levels in which increased
activation of the redox-sensitive factor NF-UB was absent.
Furthermore, MnSOD induction could only be partially
suppressed by antioxidants. We conclude that an NF-UB-
independent pathway that may not require free radical signaling
is responsible for the reduction of MnSOD induction. This
impairment could constitute both a novel defense mechanism
against iron-mediated oxidative stress in cells with mitochondrial
iron overload and conversely, an alternative source of free
radicals that could contribute to the disease pathology. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Friedreich ataxia (FRDA), the most common hereditary
ataxia, is a recessive neurodegenerative disease caused by a
partial loss of the mitochondrial matrix protein frataxin
[1,2]. FRDA patients exhibit cardiomyopathy [3] and have a
phenotype similar to that produced by severe de¢ciency of the
antioxidant vitamin E [4], consistent with the idea that, as in
other neurodegenerative diseases such as amyotrophic lateral
sclerosis, a signi¢cant component of the underlying pathology
of FRDA is cellular oxidative stress [2,5,6]. Removal of the
yeast frataxin homolog (YFH) produces gross mitochondrial
accumulation of unchelated iron, hypersensitivity to oxidative
stress-inducing agents such as hydrogen peroxide, and inhibi-
tion of mitochondrial iron-sulfur (Fe-S) proteins, most of
which can be alleviated by limiting exogenous iron availability
[5,7]. FRDA tissues and cells, which still contain residual
levels of frataxin, show similar changes of a milder nature
and also exhibit a cytotoxic response to externally added
iron [6,8^10]. In these cells, Fe-S protein impairment does
not respond to therapy with iron chelators, but can be parti-
ally corrected by treatment with antioxidants [11]. Taken to-
gether, these results suggest a model by which excess free iron
in the mitochondria of FRDA cells participates in Fenton
reactions with the reactive oxygen species (ROS) hydrogen
peroxide to generate highly reactive hydroxyl radicals which
can damage cell membranes, proteins, and DNA structures
[12,13]. The subsequent harm to the respiratory complexes
could lead to increased leakage of the ROS superoxide that
would account for the inactivation of Fe-S proteins and pos-
sibly induce even greater free iron accumulation [14]. The
validity of this model is called into question by the observa-
tions that restoration of normal mitochondrial iron levels in
yeast null strains does not restore activity of the mitochon-
drial Fe-S protein aconitase [7] and that in mouse-de¢cient
strains, inhibition of Fe-S proteins appears to precede iron
buildup [15], suggesting that these abnormalities do not result
from iron-induced hydroxyl radical damage.
The mitochondrial enzyme manganese superoxide dismu-
tase (MnSOD) is one of the primary proteins involved in
cellular defense against oxidative stress and catalyzes the
step immediately upstream of the Fenton reaction, namely
the conversion of superoxide into the stabler hydrogen per-
oxide [16,17]. Overexpression of the protein has well-docu-
mented anti-apoptotic e¡ects [18^20] and its deletion in mice
leads to neurodegeneration and cardiomyopathy [21,22].
MnSOD exhibits complex regulation by a variety of factors
that generate oxidative stress, including proin£ammatory cy-
tokines such as tumor necrosis factor-K (TNF-K) which serve
as strong inducers of expression [23^26]. For some stimuli, the
early response factor nuclear factor-UB (NF-UB) is the pri-
mary upstream mediator of induction, although ATF-1/
CREB-1, AP-2, and other factors may also modulate expres-
sion [27^29]. Free radical species, especially hydroxyl radical,
serve as key signalling molecules in NF-UB activation and
probably account for at least part of the redox sensitivity in
MnSOD expression [30,31].
In this study, we sought to address the inconsistencies in the
proposed model of FRDA pathology by using MnSOD ex-
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pression and NF-UB induction as molecular markers to con-
¢rm increases in Fenton-based oxidative stress in FRDA ¢-
broblasts exposed to high levels of external iron. Furthermore,
we hoped to delineate the speci¢c roles of NF-UB and ROS in
the regulation of MnSOD by exogenous iron and to determine
if di¡erences in MnSOD expression might account for some
of the biochemical defects in FRDA.
2. Materials and methods
2.1. Cell culture
Primary ¢broblast lines were established from patients diagnosed
with classical FRDA and normal, una¡ected controls. PCR analysis
was used to con¢rm and size the presence of alleles containing GAA
hyperexpansions in FRDA cells [1]. All experiments were conducted
on lines between passages 7 and 12 maintained under 5% CO2 in
modi¢ed Eagle’s medium containing 10% fetal bovine serum and anti-
biotics.
2.2. RNA analysis
Fibroblasts were incubated 18 h with 200 Wg/ml ferric ammonium
citrate (FAC), followed by direct Trizol extraction of RNA (Gibco).
Determination of expression levels by microarray analysis was done
essentially as described elsewhere [32]. Brie£y, total RNA was used for
cDNA synthesis followed by in vitro transcription with a T7 promoter
primer having a poly-T tail. The resulting product was hybridized and
processed with the GeneChip system (A¡ymetrix) to a HuGeneFL
DNA microarray containing oligonucleotides speci¢c for approxi-
mately 7000 human transcripts. Data analysis was performed with
Microarray Suite Software v3.3. For Northern analysis, total RNA
(8 Wg) was run on a 1% formaldehyde/MOPS gel system and probed
with 32P-labeled probes for a 276-bp mouse L-actin fragment (Am-
bion) and a 772-bp human MnSOD fragment ampli¢ed with the prim-
ers 5P-CGGGGTACCCGGCGGCATCAGCGGTACG-3P and 5P-
CGGGGTACCCTGCAGTACTCTATACCACTAC-3P. Transcript
levels were estimated by densitometric scanning of the autoradio-
graphs.
2.3. Nuclear extract preparation
Extracts were prepared as described previously [33]. Brie£y, 5U105
cells (10-cm dishes) were incubated with or without 200^800 Wg/ml
FAC for 12 or 18 h, respectively, then trypsinized, washed once with
ice-cold Tris-bu¡ered saline (100 mM Tris, pH 7.5, 150 mM NaCl),
and resuspended in swelling bu¡er (10 mM HEPES, pH 7.9, 10 mM
KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF). After 15 min on
ice, the cells were lysed with 0.6% Nonidet P-40 detergent, vigorously
vortexed for 10 s, then centrifuged at 15 000Ug for 30 s to recover the
nuclear pellet. The pellet was resuspended in extract bu¡er (20 mM
HEPES, pH 7.9, 10% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM
DTT, 1 mM PMSF) and agitated for 30 min before centrifugation at
15 000Ug for 5 min. Nuclear protein concentrations in the superna-
tant were determined by Bradford assay (Bio-Rad).
2.4. Electrophoretic mobility shift assay
Nuclear extracts (5 Wg) were incubated with 25 000 cpm of a 22-bp
NF-UB consensus oligonucleotide (Promega) that had been previously
end-labeled with [Q-32P]ATP (3000 Ci/mmol, Amersham-Pharmacia
Biotech) by T4 polynucleotide kinase. Incubations were done for 20
min at room temperature in binding bu¡er (10 mM Tris, pH 7.5, 9%
glycerol, 1 mM MgCl2, 1.5 mM EDTA, 1.5 mM DTT, 250 mM
NaCl) containing 0.5 Wg poly(dIbdC) as a non-speci¢c competitor.
For competition experiments, excess unlabeled NF-UB or SP1 oligo-
nucleotides (Promega) were added to the binding bu¡er 10 min before
addition of radiolabeled probe.
2.5. Pharmacological manipulation and Western blot analysis
Fibroblasts (5-cm dish) were grown to 70^80% con£uence and ex-
posed to either FAC (200^800 Wg/ml; Fisher Scienti¢c), TNF-K (1 ng/
ml; Sigma), hydrogen peroxide (H2O2) (30 WM; Sigma), or paraquat
(500 WM; Sigma) for up to 20 h to induce MnSOD expression. To
Fig. 1. Transcriptional induction of MnSOD by iron loading is impaired in FRDA ¢broblasts. FRDA and control (CNTL) ¢broblasts were
cultured for 18 h in the absence (3) or presence (+) of FAC (200 Wg/ml) to induce MnSOD expression. The 4.2-kb transcript of MnSOD was
evaluated by Northern blot analysis of total RNA (8 Wg/lane) as described in Section 2 using L-actin to control for RNA loading (A). FRDA
cells expressing di¡erent levels of residual frataxin (B) were also exposed to the same iron stress, and protein levels of MnSOD were measured
by Western blot (4 Wg/lane) using L-tubulin as a loading control (C). The number of GAA repeats in the shorter disease allele of these cell lines
was determined by PCR as an additional marker of residual frataxin levels. Dosage e¡ect of iron loading was evaluated by culturing cells with
the increasing amounts of FAC indicated (D) for 18 h. The results are representative of those obtained from two independent experiments.
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examine the e¡ects of antioxidants, cells were pretreated for 1 h with
N-acetyl-L-cysteine (NAC; 30 mM; Sigma), glutathione ethyl ester
(GSH, reduced form, 25 mM; Sigma), sodium formate (50 mM;
Sigma), or Bayer 11-7082 (20 WM; Biomol Research Labs) prior to
coincubation with one of the inducing agents. At the end of treat-
ment, cells were washed twice with phosphate-bu¡ered saline, imme-
diately harvested by scraping with hot SDS bu¡er (125 mM Tris, pH
6.8, 4% SDS, 10% glycerol, 100 mM DTT), and sonicated brie£y.
Protein concentrations were determined by a modi¢ed Lowry assay
(Sigma). Immunoprobing was done with MnSOD (1:10 000; Research
Diagnostics) or IUB-K (1:1000, New England Biolabs) rabbit poly-
clonal antibodies, or L-tubulin (1:100; Calbiochem) or frataxin
(1:10 000; Chemicon) mouse monoclonal antibodies. Horseradish per-
oxidase-conjugated secondary antibodies (Jackson Immunoresearch)
were detected by chemiluminescent reaction (Dupont NEN). Protein
levels were estimated by densitometric scanning of the autoradio-
graphs.
3. Results
An initial study using cDNA hybridization to DNA micro-
arrays to monitor changes in expression patterns induced by
overnight incubation of human ¢broblasts with iron revealed
a 2-fold induction of MnSOD expression in una¡ected control
cells that was surprisingly absent in FRDA ¢broblasts, a ¢nd-
ing that was con¢rmed by Northern blot analysis (Fig. 1A).
As a stimulus, the iron salt FAC was used under conditions
known to produce cellular and mitochondrial iron loading.
This lack of induction was further con¢rmed at the protein
level by immunodetection and shown to vary inversely to the
amount of residual frataxin in the cell line (Fig. 1B, C). There
was no evidence of increased basal expression of MnSOD in
FRDA cells that would account for the reduced induction.
Moreover, strong MnSOD induction could be observed in
the FRDA cells but only at higher levels of iron exposure
(Fig. 1D), con¢rming that the reduced induction resulted
from a dosage e¡ect rather than the complete inactivation
of the pathways responsible for upregulating MnSOD expres-
sion.
To examine if ROS might account for the iron-mediated
MnSOD induction, control cells were also incubated with
the intracellular superoxide generating agent paraquat and
with hydrogen peroxide. Sublethal levels were employed to
allow long term monitoring of slower translational e¡ects
while minimizing interference from cytotoxic processes such
as apoptosis, yet no induction was observed (Fig. 2A). Con-
versely, exposure to TNF-K could induce MnSOD expression
to the same degree in FRDA and control cells (Fig. 2B),
suggesting that some mechanisms of MnSOD regulation re-
mained unaltered in FRDA cells. Cotreatment of cells with
iron and the antioxidant N-acetyl-L-cysteine, the H2O2 scav-
enger reduced glutathione (not shown), or the hydroxyl rad-
ical scavenger formate, led to modest impairments of induc-
tion in all cases (approximately 50%, Fig. 3), although
expression remained substantially higher than in the untreated
cells.
Since NF-UB regulates induction of MnSOD by certain
stimuli and since it itself is sensitive to the cellular redox state,
the activity of this factor following iron loading was also
studied. At low levels of iron exposure in which potentiation
of MnSOD expression was observable, increased formation of
NF-UB-speci¢c binding complexes was undetectable by elec-
tromobility shift assay (EMSA; data not shown) and degra-
dation of the inhibitory protein IUB-K that typically precedes
NF-UB activation was also absent (Fig. 4A), while higher
levels of iron led to increases in NF-UB activity in both con-
trol and FRDA cells to an equal extent (Fig. 4B). Treatment
with the control stimulus TNF-K produced rapid loss of IUB-
K and strong activation of NF-UB (Fig. 4A, B). Coincubation
of iron-loaded cells with the anti-in£ammatory agent Bayer
11-7082, which among other properties is capable of blocking
phosphorylation of IUB-K, proved the most potent inhibitor
of iron- and TNF-K-induced MnSOD expression (Fig. 3),
bringing protein levels back down to that observed in un-
treated cells.
4. Discussion
As a whole, our results demonstrate that iron regulation of
MnSOD expression involves a complicated combination of
mechanisms. While low doses of iron can signi¢cantly increase
MnSOD protein levels via an NF-UB-independent pathway,
an NF-UB-dependent pathway also contributes synergistically
to induction at higher levels of iron. Most notably, di¡erences
in the activity of the ¢rst pathway seem to be responsible for
the surprising observation that MnSOD induction is impaired
in FRDA cells, because this di¡erential induction is observed
Fig. 2. Response of MnSOD expression to a variety of oxidative
stresses. FRDA and control (CNTL) ¢broblasts were incubated
with (+) or without (3) H2O2 (30 WM) or paraquat (500 WM), a
superoxide generating agent, for 20 h prior to analysis of MnSOD
protein levels by Western blot (4 Wg/lane), using L-tubulin as a load-
ing control (A). Exposure to the ROS generating cytokine TNF-K
(10 ng/ml) for 10 h was also evaluated (B). The results are represen-
tative of those obtained in two independent experiments.
Fig. 3. Free radical scavengers partially block MnSOD induction by
iron. Normal ¢broblasts were pretreated (+) for 1 h with the anti-
oxidant N-acetyl-L-cysteine (NAC, 30 mM), the hydroxyl radical
scavenger sodium formate (FORM, 50 mM), the IUB-K phosphory-
lation inhibiting agent Bayer 11-7082 (BAY, 20 WM), or left un-
treated (3) before being exposed for 10 h to FAC (800 Wg/ml). For
comparison, cells were pretreated with Bayer 11-7082 or left un-
treated before exposure to the alternative stimulus TNF-K. As con-
trols, some samples were treated solely with blocking agents without
exposure to stressful stimuli, or received no treatment at all (NT).
Direct extracts were used to make Western blots (4 Wg/lane) for the
analysis of MnSOD protein levels with L-tubulin serving as a load-
ing control. The results are representative of those obtained in two
independent experiments.
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at levels of iron treatment insu⁄cient to activate NF-UB. This
is further suggested by the fact that, even at levels of exposure
su⁄cient to potentiate NF-UB, there is no apparent di¡erence
in activity between control and patient cells. Results with free
radical scavengers indicate that ROS from Fenton reactions
are also important intermediaries in induction of MnSOD by
iron, but their inability to completely block induction suggests
that a ROS-independent regulatory mechanism also exists.
Given the importance of ROS signalling in NF-UB activation
and the absence of MnSOD induction by exogenous hydrogen
peroxide and paraquat, it is likely that the NF-UB-independ-
ent pathway relies on this ROS-independent mechanism.
The composition of this pathway and the reason for its
inhibition in FRDA cells is more di⁄cult to explain. AP-1
and ATF-1/CREB-1 activation have been implicated in NF-
UB-independent MnSOD induction by other stimuli [34,35].
Changes in cell proliferation and cell-cycle regulation can
also in£uence MnSOD expression and in this respect it is
notable that Bayer 11-7082, a compound known to not only
regulate IUB-K phosphorylation but activity of the mitogen-
activated protein kinases JNK-1 and p38 as well [36], was the
only substance tested that was capable of inhibiting both
pathways of iron-mediated MnSOD induction.
Limiting MnSOD activity may serve as a novel defense
mechanism that allows cells overloaded with mitochondrial
free iron to minimize production of highly toxic hydroxyl
radicals by upstream inhibition of the reaction that produces
the Fenton cofactor hydrogen peroxide. Normal cells would
not require downregulation presumably, because they remain
capable of sequestering most excess iron in an unreactive
form. Suppression of hydroxyl radical production provides a
direct route for the NF-UB-independent pathway to in£uence
the NF-UB-dependent pathway, and this secondary e¡ect
might explain our failure to observe the anticipated greater
potentiation of NF-UB activation in FRDA cells following
treatment with high levels of iron. Our results also di¡er
from those obtained with YFH-de¢cient yeast [37], which ex-
press the same level of MnSOD as wild-type cells when grown
in iron replete media containing the fermentable carbon
source glucose. The lack of di¡erential induction in these cells
might be a species-speci¢c e¡ect re£ecting the absence of the
NF-UB-independent regulatory pathway in yeast. Alterna-
tively, this pathway may be present but inactive when cells
are grown in glucose, since di¡erences in expression appear to
be heavily in£uenced by the cell respiratory activity and the
type of carbon source used.
Ironically, while reducing hydroxyl radical damage, the im-
pairment of MnSOD induction is likely to lead to other prob-
lems, including an increase in superoxide levels, which might
explain the inactivation of mitochondrial Fe-S proteins seen in
FRDA cells. Given the anti-apoptotic e¡ects of MnSOD ex-
pression and the phenotypic similarities between MnSOD null
mice and FRDA patients, this impairment might also explain
the increased susceptibility of FRDA cells to killing by iron
[9] and prove to be a major underlying factor in some aspects
of FRDA pathology. In the end, by reducing MnSOD upreg-
ulation, FRDA cells may only be prolonging an inevitable
death by exchanging overproduction of one toxic ROS for
another.
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